{
  "symbol": "OCSAW",
  "company_name": "Oculis Holding Ag Warrants",
  "ir_website": "https://investors.oculis.com/",
  "structured_data": [
    {
      "section_name": "News Releases",
      "links": [
        {
          "title": "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated",
          "url": "https://investors.oculis.com/news-releases/news-release-details/oculis-publishes-notifications-transactions-persons-0",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [ Contact Us ](https://oculis.com/contact-us/ \"Contact Us\")\n  * [ Join Us ](https://oculis.com/our-company/our-culture/#join-us \"Join Us\")\n  * [ LinkedIn ](https://www.linkedin.com/company/oculis-sa/ \"LinkedIn\")\n\n\n\n[ ![Oculis Logo](/sites/g/files/knoqqb92306/themes/site/client_site_202/dist/images/oculis-logo.svg) ](https://oculis.com/ \"Oculis\")\n\nWhat can we help you find?\n\n# Release Details\n\n![](/sites/g/files/knoqqb92306/themes/site/client_site_202/dist/images/content/hero-overview.jpg)\n\n  * [Overview](/investors-media)\n  * [Stock](/stock-information)\n  * [News](/news)\n  * [Events](/events)\n  * [Governance](/governance)\n  * [SEC Filings](/sec-filings)\n  * [Disclosures](/disclosures)\n  * [FAQs](/faqs)\n  * [Resources](/resources)\n  * [Extra menu]()\n  * [Extra menu]()\n  * [Extra menu]()\n\n\n\n## \n\nOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated\n\nNov 29, 2024\n\n[PDF Version](/node/8281/pdf)\n\nZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.\n\n**Attachments**\n\n  * [Notification of managers' transaction - Anthony Rosenberg](https://ml-eu.globenewswire.com/Resource/Download/b82cb0d3-5f97-47f3-ad83-bd27e70f0164)\n  * [Notification of managers' transaction - Riad Sherif](https://ml-eu.globenewswire.com/Resource/Download/5120a138-0560-40c4-a9da-a9f178e74b22)\n  * [Notification of managers' transaction - Sylvia Cheung](https://ml-eu.globenewswire.com/Resource/Download/5e0cbd20-51bd-4813-8142-f6e2d5a9cf01)\n  * [Notification of managers' transaction - Pall Johanesson](https://ml-eu.globenewswire.com/Resource/Download/2ee4e030-dbf5-4256-aff8-903d179ca963)\n\n![](https://ml-eu.globenewswire.com/media/NjE3NWJkNjMtNGVkMy00ODI4LWEzZGYtZDFjY2ZhNzc4Njk1LTEyMDA1NzY=/tiny/Oculis-Holding-AG.png)\n"
        },
        {
          "title": "Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities",
          "url": "https://investors.oculis.com/news-releases/news-release-details/oculis-publishes-notification-transaction-person-discharging",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [ Contact Us ](https://oculis.com/contact-us/ \"Contact Us\")\n  * [ Join Us ](https://oculis.com/our-company/our-culture/#join-us \"Join Us\")\n  * [ LinkedIn ](https://www.linkedin.com/company/oculis-sa/ \"LinkedIn\")\n\n\n\n[ ![Oculis Logo](/sites/g/files/knoqqb92306/themes/site/client_site_202/dist/images/oculis-logo.svg) ](https://oculis.com/ \"Oculis\")\n\nWhat can we help you find?\n\n# Release Details\n\n![](/sites/g/files/knoqqb92306/themes/site/client_site_202/dist/images/content/hero-overview.jpg)\n\n  * [Overview](/investors-media)\n  * [Stock](/stock-information)\n  * [News](/news)\n  * [Events](/events)\n  * [Governance](/governance)\n  * [SEC Filings](/sec-filings)\n  * [Disclosures](/disclosures)\n  * [FAQs](/faqs)\n  * [Resources](/resources)\n  * [Extra menu]()\n  * [Extra menu]()\n  * [Extra menu]()\n\n\n\n## \n\nOculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities\n\nNov 27, 2024\n\n[PDF Version](/node/8276/pdf)\n\nZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the Company.\n\n**Attachment**\n\n  * [Notification of managers' transaction - Arshad Khanani - Nov 2024](https://ml-eu.globenewswire.com/Resource/Download/a9762183-483a-4bb0-a3e8-57fdd73651ff)\n\n![](https://ml-eu.globenewswire.com/media/OTdkNDU5MDgtYWI2OC00MTRmLWIzNzgtOGIyNjUwYTQzOWE2LTEyMDA1NzY=/tiny/Oculis-Holding-AG.png)\n"
        },
        {
          "title": "Oculis to Present at the Stifel 2024 Healthcare Conference",
          "url": "https://investors.oculis.com/news-releases/news-release-details/oculis-present-stifel-2024-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [ Contact Us ](https://oculis.com/contact-us/ \"Contact Us\")\n  * [ Join Us ](https://oculis.com/our-company/our-culture/#join-us \"Join Us\")\n  * [ LinkedIn ](https://www.linkedin.com/company/oculis-sa/ \"LinkedIn\")\n\n\n\n[ ![Oculis Logo](/sites/g/files/knoqqb92306/themes/site/client_site_202/dist/images/oculis-logo.svg) ](https://oculis.com/ \"Oculis\")\n\nWhat can we help you find?\n\n# Release Details\n\n![](/sites/g/files/knoqqb92306/themes/site/client_site_202/dist/images/content/hero-overview.jpg)\n\n  * [Overview](/investors-media)\n  * [Stock](/stock-information)\n  * [News](/news)\n  * [Events](/events)\n  * [Governance](/governance)\n  * [SEC Filings](/sec-filings)\n  * [Disclosures](/disclosures)\n  * [FAQs](/faqs)\n  * [Resources](/resources)\n  * [Extra menu]()\n  * [Extra menu]()\n  * [Extra menu]()\n\n\n\n## \n\nOculis to Present at the Stifel 2024 Healthcare Conference\n\nNov 13, 2024\n\n[PDF Version](/node/8266/pdf)\n\nZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY.\n\nSylvia Cheung, Chief Financial Officer of Oculis, will participate in a fireside chat on November 18, 2024 at 3:35 pm ET. A live webcast of the fireside chat will be available [_here_](https://www.globenewswire.com/Tracker?data=6M0efH2z86pZmZZ-Wb5NQro77UYMasNjtzOY2YEhhjFV--b1bEEey5ZAztjZSWeIDKot2_WsHG-pm8-HgZ791ojKf08eSJBhOXqa4nlsI1_1IYgfQfx8dljTfi33L12VIajIK9Wfeh-K8f5iaMCVPkK9tPObM0GcQgOxwgldPRwlhs5uZf_OCN6CDnRg3dJ7RTHxnDfbNJ410XBQFJjaxw==). \n\nThe Company will be available for one-on-one meetings during the conference. Interested investors should contact their Stifel representative to request meetings. A link to access the fireside chat, when available, will be posted to Oculis website on the [_Events & Presentation_](https://www.globenewswire.com/Tracker?data=zHDI1UYRLzDaFvhIxC4ZlXwt5NuW36amRMH4dV_2ywt6oGVSpN-qQ-wWsqlsjy_Zy8MCCfh4wqLtf-HWTUXZjtE5xSZSk1vMznInVmkM8olsqml8DLPE9rNgOwNQRlhB) page under the Investors & Media section.\n\n**-ENDS-**\n\n**About Oculis**\n\nOculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. \n\nFor more information, please visit: [_www.oculis.com_](https://www.globenewswire.com/Tracker?data=en6Ro2Zc2OSBCOPjWWgFVHR4wTYMtlL8ZJ_SDbeMEI8n8GwZqcoXUvp5DDhYtDvtzQLCNZwiSJ80W-umOD8LOQ==)\n\n**Oculis Contacts** Ms. Sylvia Cheung, CFO [_sylvia.cheung@oculis.com_](https://www.globenewswire.com/Tracker?data=acGJ-SL7M_fY4bXwodeatQcHqteGIQi1PuG1BzWWzPR0TH_IfV50Uq3N3GkdsncWMvfhC5ATKfOZcfZnEia9LjZxNzxa-RCmJ82AahCoj-AuBBJI-9y4QOUJ-lVrIiYcNsBdQpaUU151IvelVcSzV9ZsF0gveGabYI07tGRzhsotPE9XmO3gbOhgcldczvsI3A_RuY1NwvuRMOdgw8TmV7cAxBq2qztPH0o_TMPeiswStul5QvKomTeuDOaqlSuZJXPrL96DSzq7aLCjMMY5fI0zWraUMRp9gojw5-YWboE=)\n\n**Investor & Media Relations **LifeSci AdvisorsCorey Davis, Ph.D.[_cdavis@lifesciadvisors.com_](https://www.globenewswire.com/Tracker?data=6n0vESumSlS75_b9CDIEnx4gf9ODqtbX2dNmUdgs_Pxcgim5jxP7VKb743s2fuHvbeCTq7AJa5euPZMSIq6XU_eYd1g_q581h3ETXKFH3LtOY6srD0wQ6GaX1rEdM-L7)\n\n1-212-915-2577 \n\n![](https://ml-eu.globenewswire.com/media/ODA3NmQ5NzItMTkyOC00OTc5LWFjZjQtMGZjMjRkMDY4MzY3LTEyMDA1NzY=/tiny/Oculis-Holding-AG.png)\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": []
    },
    {
      "section_name": "Corporate Governance",
      "links": []
    },
    {
      "section_name": "SEC Filings",
      "links": []
    },
    {
      "section_name": "Public Disclosures",
      "links": []
    },
    {
      "section_name": "Investor FAQs",
      "links": []
    },
    {
      "section_name": "Investor Resources",
      "links": []
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Stock Information",
          "url": "https://investors.oculis.com/stock-information",
          "content": "[Skip to content](#lfg-main-content)\n\n  * [ Contact Us ](https://oculis.com/contact-us/ \"Contact Us\")\n  * [ Join Us ](https://oculis.com/our-company/our-culture/#join-us \"Join Us\")\n  * [ LinkedIn ](https://www.linkedin.com/company/oculis-sa/ \"LinkedIn\")\n\n\n\n[ ![Oculis Logo](/sites/g/files/knoqqb92306/themes/site/client_site_202/dist/images/oculis-logo.svg) ](https://oculis.com/ \"Oculis\")\n\nWhat can we help you find?\n\n# Stock Information\n\n![](/sites/g/files/knoqqb92306/themes/site/client_site_202/dist/images/content/hero-overview.jpg)\n\n  * [Overview](/investors-media)\n  * [Stock](/stock-information)\n  * [News](/news)\n  * [Events](/events)\n  * [Governance](/governance)\n  * [SEC Filings](/sec-filings)\n  * [Disclosures](/disclosures)\n  * [FAQs](/faqs)\n  * [Resources](/resources)\n  * [Extra menu]()\n  * [Extra menu]()\n  * [Extra menu]()\n\n\n\n## Stock Quote\n\nChange\n\nVolume\n\nToday's Open\n\nPrevious Close\n\nToday's High\n\nToday's Low\n\n52 Week High\n\n52 Week Low\n\n## Stock Chart\n\n## Historical Lookup\n\nSymbol OCSOCS.IC\n\nLookup Month JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember\n\nLookup Day 12345678910111213141516171819202122232425262728293031\n\nLookup Year 20232024\n\nLookup Month JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember\n\nLookup Day 12345678910111213141516171819202122232425262728293031\n\nLookup Year 20232024\n\nLeave this field blank\n\n## Week of November 25, 2024\n\nDate Requested | Open Price | Day High | Day Low | Closing Price | Volume | Split Adjustment Factor  \n---|---|---|---|---|---|---  \nNov 25, 2024 | $14.82 | $14.89 | $14.61 | $14.79 | 40,632 | 1:1  \nNov 26, 2024 | $14.86 | $15.50 | $14.86 | $15.37 | 40,113 | 1:1  \nNov 27, 2024 | $15.51 | $16.32 | $15.51 | $16.16 | 56,065 | 1:1  \nNov 29, 2024 | $16.15 | $16.15 | $16.00 | $16.04 | 32,043 | 1:1  \n  \nNOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.\n\n## Investment Calculator\n\nERROR \n\nReturn calculations do not include reinvested cash dividends.\n\n##  Analyst Coverage \n\nFirm | Analyst  \n---|---  \nBaird |  Colleen Kusy   \nBank of America Securities |  Jason M. Gerberry   \nChardan |  Daniil Gataulin   \nH.C. Wainwright & Co. |  Yi Chen   \nLeerink Partners |  Marc Goodman   \nPareto Securities |  Dan Akschuti   \nStifel |  Annabel Samimy   \nVan Lanschot Kempen |  Sushila Hernandez   \n  \nOculis is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Oculis's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Oculis or its management. Oculis does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\nMinimum 15 minutes delayed. Source: LSEG\n"
        }
      ]
    }
  ]
}